Akumin — Q3 2022 Earnings Presentation
15 slides from Akumin's earnings presentation, Nov 10, 2022
Slide 1: Q3 2022 Results
Akumin Inc. Q3 2022 Results November 10, 2022 Riadh Zine, Chairman & CEO David Kretschmer, Chief Financial Officer
Slide 2: Disclaimer and Disclosure
Disclaimer and Disclosure Forward-Looking Statements This presentation may contain forward-looking information or forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and/or applicable Canadian securities legislation (collectively, “forward-looki
Slide 3: Q3 2022 Performance Highlights
Q3 2022 Performance Highlights • Same Store Volumes on a pro forma basis across the platform continued to trend positively, except for Oncology Patient Starts: • MRI: +0.2% • PET/CT: +7.8% • Total Radiology Procedures: (2.5%) • Total Oncology Patient Starts: (0.2%) • Revenue of $186.6M, up 72.5% vs.
Slide 4: Integration and Operations Update
Integration and Operations Update • Integration Progress • Synergy achievement: We continue to expect to achieve the full run-rate benefit of $23mm of cost synergies as part of our Phase 1 integration efforts. • Future synergies: We have identified an additional $25mm in synergies that we expect to
Slide 5: Oncology Strategy Refinement
Oncology Strategy Refinement • A Core Business • As previously stated, oncology is a core offering to our hospital and health system partners and is complimentary to our radiology business. • As part of our transformation plan, we refined our strategic focus to capitalize on the market dynamics and
Slide 6: Diverse Service Lines and Modalities
Diverse Service Lines and Modalities Service Lines (% of Revenue) 1 • Diversification of revenue Radiology Procedure Mix between Radiology and (% of Revenue) Oncology divisions • Akumin provides a full suite 21% of radiology and oncology services with a focus on 55% high-growth and high- 24% value m
Slide 7: Diverse Payer Mix
Diverse Payer Mix TTM Q3’22 Pro Forma Payer Mix1 ~95% of the company’s overall (% of Revenue) revenue is derived from outpatient procedures • 51% of revenue is received via third party and government payers, and reimbursed at outpatient rates • 49% of revenue is received via health systems and hospi
Slide 8: Radiology Volume Trends
Radiology Volume Trends • Same Store MRI Volume Growth: +0.2% in Q3 2022 • Same Store PET/CT Volume Growth: +7.8% in Q3 2022 • Same Store Total Procedures Volume Growth: (2.5%) in Q3 2022 Same Store Volume Growth1 MRI Procedures PET/CT Procedures Total Procedures 54.2% 20.6% 44.3% 7.1% 6.4% 7.8% 8.5
Slide 9: Oncology Volume Trends
Oncology Volume Trends • Same Store Patient Start Volume Growth: (0.2%) in Q3 2022 • Patient Start Volume is relatively stable, having returned to pre-pandemic levels • Revenue/Patient Start is down slightly due to product mix (SRS vs. Linac) Same Store Patient Start Volume Growth1 Total – Patient S
Slide 10: Segment Financial Performance
Segment Financial Performance Q3 2022 TTM Pro Forma1 as of Q3 2022 ($ in M) RAD ONC Corp Total ($ in M) RAD ONC Corp Total Revenue $155.1 $31.5 $186.6 Revenue $617.2 $125.5 $742.7 Adjusted EBITDA2 $31.2 $11.0 $(5.7) $36.5 Adjusted EBITDA2 $117.1 $42.8 $(24.8) $135.1 Adjusted EBITDA Adjusted EBITDA 2
Slide 11: 2022 Guidance Revised
2022 Guidance Revised • Revising our full-year Revenue and Adjusted EBITDA Guidance • Several factors have resulted in a revision to our outlook for full-year 2022: - The impact of Hurricane Ian on our Q3 results; - Ongoing labor constraints impacting capacity utilization in some facilities; - The i
Slide 12: Free Cash Flow Generation
Free Cash Flow Generation As we exit 2022, the company FY2022 FY2022 (in millions) FY2021(1) expects to generate free cash MidPoint Exit Rate flows of over $50M on a go- forward basis as per the following Adjusted EBITDA $66.9 $145.0 $178.2(2) assumptions: Less: • Exit rate of the revised 2022 guida
Slide 13: Capital Structure – A Solid Foundation for Growth
Capital Structure – A Solid Foundation for Growth Akumin’s capital structure is comprised Adjusted EBITDA1 $145.0 of a diverse set of capital providers including traditional banks, bondholders Total Secured Debt $921.7 and Stonepeak as debt and equity stakeholders. Less: Cash 59.4 Net Secured Debt $
Slide 14: Thank you!
Thank you! Riadh Zine, Chairman & CEO David Kretschmer, Chief Financial Officer
Slide 15: Appendix 1: Reconciliation of Net Loss to Adjusted EBITDA
Appendix 1: Reconciliation of Net Loss to Adjusted EBITDA Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2022 2021 2022 2021 Net income (loss) $ (49,745) $ 1,180 $ (102,256) $ (8,182) Interest expense 29,679 16,932 87,650 34,221 Income tax expense (benefit) 12,038 (2